National Cancer Institute, Research Contracts Branch, PCCS, 6120 Executive Blvd, EPS/Room 635, Bethesda, MD 20892-7226

A -- EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VITRO TECHNIQUES SOL MAA-N01-CN-65015-63 DUE 032596 POC Tina Huyck, Contracting Officer Representative, Clyde Williams, Contracting Officer, 301-496-8603. The National Cancer Institute, Division of Cancer Prevention and Control (DCPC), Chemoprevention Branch, in its annual requirement to seek new sources, is soliciting proposals for the Evaluation of Chemopreventive Agents by in Vitro Techniques to increase the number of Master Agreement (MA) Holders. Current MA Holders for this program are not required to submit a proposal. This Master Agreement Announcement (MAA) is issued to solicit MA Holders who have adequate capabilities and technical expertise to screen and evaluate the activity of chemopreventive agents in various In Vitro assays of cell transformatoin. Agents with potential chemopreventive activity are identified by epidemiologic surveys, initial laboratory (experimental) findings, observations in the clinical setting, or structural homology with agents having known chemopreventive activity. A rigorous and systematic evaluation of these candidate agents is necessary before their efficacy can be examined in clinical trials for cancer prevention. In Vitro screening and evaluation techniques measuring the ability of these chemopreventive agents to inhibit transformation provides a relatively rapid and efficient means of qualifying these agents for further evaluation for the prevention of cancer in humans. Some of the agents to be used in this project are potentially hazardous. The In Vitro systems may involve the use of carcinogens, other hazardous chemicals and human tissue in culture. Laboratory practices shall be employed which will keep any element of risk to personnel at an absolute minimum. Where indicated, tissue and compound handling must be performed in (at least) Class I laminar flow cabinets which must meet NIH specifications for work with these agents. The offeror shall comply with NCI safety standards for research involving chemical carcinogens (DHHS Publication No. NIH-76-900). It shall be required that the facilities have operating tissue culture/cell biology and chemistry laboratories which are suitable for using hazardous and/or carcinogenic materials as test materials. The contractor must have or be able to obtain all the equipment necessary to accomplish the studies, including but not limited to, laminar flow hoods, CO2 incubators, equipment for sterility testing, isotope counters, spectrophotometer, hazardous chemical storage cabinets and refrigerators, equipment such as microscopes and miscellaneous laboratory equipment. The laboratory shall have or have access to appropriate terminal and computer facilities and equipment for data collection and storage. The period of performance of the Master Agreement (MA) pool will be three (3) years. It is estimated that up to four (4) Master Agreement Orders per year will be issued pursuant to the Master Agreements. Requests for this solicitation must be in writing and reference MAA No. N01-CN-65015-63. The Master Agreement Announcement (MAA) will be available approximately February 23, 1996 and due approximately March 25, 1996. Requests should be addressed/mailed to Ms. Tina Huyck, Contracting Officer Representative, National Institutes of Health, National Cancer Institute, Research Contracts Branch, PCCS, Executive Plaza South, Room 635, 6120 Executive Boulevard MSC 7226, Bethesda, Maryland 20892-7226. If you would like to FAX in your request, our FAX number is 301-402-8579. No collect calls will be accepted (0038)

Loren Data Corp. http://www.ld.com (SYN# 0003 19960208\A-0003.SOL)